纤维化是诸多慢性疾病进展至终末期的共同病理转归，目前针对纤维化的治疗选择十分有限，患者远期预后欠佳。黄芩苷可通过调控核心信号通路、抑制NOD样受体蛋白3炎症小体活化、减轻氧化应激、调控细胞外基质和上皮-间充质转化发挥抗纤维化的药理作用。总结了黄芩苷抗纤维化的药理作用研究进展，为其临床应用提供依据。

Fibrosis is a common pathological outcome of many chronic diseases that progress to the terminal stage. Currently, clinical treatment options for fibrosis are very limited, and the long-term prognosis of patients is poor. Baicalin can exert anti-fibrotic pharmacological effects by regulating core signaling pathways, inhibiting NOD like receptor protein 3 inflammasome activation, reducing oxidative stress, and regulating extracellular matrix and epithelial mesenchymal transition. This article summarizes the research progress on the pharmacological effects of baicalin against fibrosis, providing a basis for its clinical application.

R285.5

上海市卫生健康委员会项目（201640098）；上海市虹口区卫健委项目（HKZYY-2025-19）；上海市虹口区卫生健康委员会临床重点扶持专科建设项目（HKZK2020A0）